VCST yields 1000000.00% · ABBV yields 3.06%● Live data
📍 VCST pulled ahead of the other in Year 1
Combined, VCST + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VCST + ABBV for your $10,000?
ViewCast.com, Inc., doing business as ViewCast Corporation, develops hardware and software for the capture, management, and delivery of video over IP and mobile networks. The company's products include Osprey Video line of capture cards for video acquisition/capture/streaming; and Niagara Streaming Systems and Software, which provide pre-configured, plug-and-play solutions enabling the user to encode and stream audio and video over the Internet or corporate network. It also provides professional services and support; and complementary products and technologies from third party providers. The company serves various markets, including broadcasters, content delivery networks, and narrowcasters; federal, state, and local governments; small, medium, and large enterprises; mobile and cable providers; education and training; retail and consumer package goods; digital signage integrators; and other industry verticals, such as advertising, medical, and insurance. ViewCast.com, Inc. markets and sells its products and professional services directly to end-users or through indirect channels comprising original equipment manufacturers, value-added resellers, resellers, distributors, and computer system integrators worldwide. The company was formerly known as MultiMedia Access Corporation and changed its name to ViewCast.com, Inc. in April 1999. ViewCast.com, Inc. was founded in 1994 and is headquartered in Plano, Texas.
Full VCST Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.